Another new coronavirus inactivated vaccine entered Phase II clinical trials.

"In the current global epidemic is still serious and complex situation, our months of efforts to fight the global epidemic once again a strong shot.
" the head of the Institute of Biology of the Academy of Medical Sciences told Science and Technology Daily.
Since the outbreak of new crown pneumonia, the Institute of Medicine, which has successfully developed China's first Sabin strain polio inactivated vaccine and enterovirus EV71 inactivated vaccine, under the overall deployment of the CPC Central Committee and the State Council, under the leadership of the Chinese Academy of Medical Sciences, has undertaken the task of research and development of epidemic prevention and control, set up an emergency vaccine research and development team, and carried out research and research on emergency vaccine research, animal model establishment, virus traceability and transmission mechanism.
through comprehensive multidisciplinary efforts to speed up scientific research, in adherence to science, to ensure safety on the basis of accelerating the progress of vaccine research and development.
At the beginning of February this year, the Institute of Biology of the Academy of Medicine has started the work of virus isolation and breeding, and in the cells to adapt to the generational culture, completed the screening and identification of vaccine production poisons, established a three-level seed bank and passed the China Food and Drug Inspection Research Institute.
the resource advantages of the National Kunming High-Level Biosecurity Primate Research Center, a model of rhesus monkey animals for vaccine safety and conservation evaluation was initially established.
March, a study on the pathogenic mechanism and immunology of SARS-CoV-2 infection was carried out, which laid a solid foundation for vaccine research and development, determined the key production process system of vaccine and the standard system of quality control, and completed the evaluation of the safety, immunogenicity and protection effect of vaccine in non-human primates.
technology daily reporter learned that on May 13, the Institute of Biological Sciences received the "Drug Clinical Trial Approval" issued by the State Drug Administration, approved the implementation of phase I./II. clinical trials.
May 15, the phase I clinical study was officially launched at Huaxi Second Hospital of Sichuan University, using a randomized, double-blind, placebo-controlled design, which was gradually advanced according to the trial program.
, nearly 200 healthy adults aged 18 to 59 have been admitted to the group and successfully completed Phase I clinical trials.
phase II. First population clinical study, officially launched on June 20, will further evaluate the immunogenicity and safety of vaccination in healthy populations and determine immunization procedures and doses.
II. Phase II clinical studies were organized and implemented by the Vaccine Clinical Research Center of the Yunnan Provincial Center for Disease Control and Prevention, and the screening was initiated simultaneously at two research sites of the Center for Disease Control and Prevention in Myler City, Yunnan Province, and the Center for Disease Control and Prevention in the old city of Yunnan Province.
against the backdrop of a global pandemic of the new crown pneumonia epidemic, vaccines are the best hope for an effective solution to the crisis.
" as a national public welfare institutions, the Institute of Medical Sciences biology practice 'national team' mission to assume, adhering to a rigorous scientific attitude, relying on the national biosecurity major scientific and technological infrastructure support, make full use of the important technical reserves for major human infectious diseases, and steadily promote the clinical research of the new coronavirus inactivated vaccine.
" the person in charge said that they will do their utmost to provide the people with safe, effective and controlled quality vaccines at an early time, in order to protect people's lives and health, maintain national public health security and the global response to the new crown pneumonia epidemic to make new contributions.
Previously, the research on the new coronavirus inactivated vaccine of the Institute of Biology of the Academy of Medicine has achieved phased results, while actively carrying out clinical trials, the industrialization of the implementation of the work is also steadily advancing, the Kunming vaccine industry base planning and design with biosecurity protection GMP production workshop, for the industrialization of the new corona inactivated vaccine implementation, is expected to be put into use in the second half of 2020 to ensure the national emergency vaccine supply task.
Institute of Biological Sciences has long been engaged in the development and production of viral vaccines.
1957, gu Fangzhou, an older generation of scientists, was appointed to lead a research team to begin polio research.
Institute of Biological Sciences has developed and produced live polio vaccine and Sabin strain polio inactivated vaccine, which is available nationwide and protects hundreds of thousands of children from disability.
According to the Ministry of Science and Technology, the National Health and Health Commission on June 19, China's scientific research team in accordance with inactivated vaccine, genetic engineering recombinant sub-unit vaccine, adenovirus vector vaccine, anti-virus virus vector vaccine and nucleic acid vaccine and other 5 technical routes, a total of 12 vaccine research and development tasks.
, clinical trials have been conducted on one adenovirus vector vaccine and four inactivated vaccines, accounting for 40% of the total number of vaccines conducted worldwide.
.